CódigoEEN TRFR20251009013
Alta en la Red: 14/10/2025
Deadline: 9/10/2026
Tipo: Demanda

Descripción A french biotech start-up dedicated to the development of muscle secretome-based biotherapies to cure type 1 (T1D) and type 2 (T2D) diabetes is interested to develop breakthrough therapies. Main objective is to alleviate the burden of daily diabetes management and eliminate severe complications like renal failure, heart attack and so on. Partners specialized in T1D, stem-cells, immune modulating specialists, bioproduction, biomarker analysis, are sought under technological and/or R and D agreement.

Si desea más información sobre la oportunidad tecnológica, envíe un e-mail indicando la referencia a CONTACTO